Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$149.96 USD
+6.01 (4.18%)
Updated May 1, 2024 04:00 PM ET
After-Market: $149.79 -0.17 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.96 USD
+6.01 (4.18%)
Updated May 1, 2024 04:00 PM ET
After-Market: $149.79 -0.17 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.
Endo (ENDP) Beats Q2 Earnings & Sales, 2017 Guidance Lowered
by Zacks Equity Research
Endo (ENDP) beat second-quarter 2017 earnings and sales. However, revenues were down on a year over year basis due to generic competition adversely impacting the branded established products portfolio.
3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings
by Zacks Equity Research
The first half has been pretty strong for companies in the space.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) reported another quarter of lackluster Belviq sales. However, the company is expected to advance ralinpeg in phase III study soon based on positive phase II study results.
Why Alnylam Pharmaceuticals (ALNY) Might Surprise This Earnings Season
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth
by Zacks Equity Research
On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).
Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.
Are Medicines Company's Key Drugs Set for Growth in 2017?
by Zacks Equity Research
On Jul 7, 2017, we issued an updated report on The Medicines Company (MDCO).
Alnylam Commences Phase III Study for Hemophilia Candidate
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.
Biotech Stock Roundup: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod
by Arpita Dutt
Key highlights in the biotech sector include FDA approval for Portola's (PTLA) anticoagulant and EU approval for Regeneron's rheumatoid arthritis (RA) drug.
Why is Alnylam's (ALNY) Stock Close to 100% this Year?
by Zacks Equity Research
Shares of Alnylam Pharmaceuticals, Inc. (ALNY) soared 93.3% this year so far massively outperforming the 2.6% increase registered by the Zacks classified Biomed/Genetics industry during this period.
Why Is Alnylam (ALNY) Up 31.2% Since the Last Earnings Report?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam's Givosiran Gets Breakthrough Therapy Status by FDA
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) announced that it has received Breakthrough Therapy designation from the FDA for pipeline candidate givosiran (ALN-AS1), for the prophylaxis of attacks in patients with acute hepatic porphyria (AHP).
Regeneron Presents Positive Phase II Data on HoFH Candidate
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) presented positive phase II data, evaluating its investigational angiopoietin-like 3 (ANGPTL3) antibody, evinacumab at the National Lipid Association's (NLA) Scientific Sessions.
Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline
by Zacks Equity Research
We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.
Alnylam Pharmaceuticals (ALNY) Looks Good: Stock Jumps 16.3%
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) shares jump a little above 16% in the last trading session.
Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.
The Medicines Company (MDCO) Q1 Loss Wider Than Expected
by Zacks Equity Research
The Medicines Company (MDCO) reported loss $1.44 per share, wider than the Zacks Consensus Estimate of a loss of $1.13.
5 Reasons Why Sanofi (SNY) is a Good Stock to Buy Now
by Zacks Equity Research
Paris, France based Sanofi (SNY) is a global healthcare company possessing a diversified product portfolio.
Regeneron's Evinacumab Gets Breakthrough Therapy by FDA
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has granted Breakthrough Therapy Designation status to ievinacumab for the treatment patients with Homozygous Familial Hypercholesterolemia.
Alnylam (ALNY) Up 14.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam's LDL-Lowering Drug Positive in Phase II Study
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) and its partner The Medicines Company (MDCO) announced positive final results from the phase II study, ORION-1, on their experimental PCSK9 inhibitor, inclisiran.
Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.
The Medicines Co LDL-Lowering Drug Positive in Phase II
by Zacks Equity Research
The Medicines Company (MDCO) announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.
Alnylam Reports Positive Data on Fitusiran, Givosiran
by Zacks Equity Research
Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.